Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 1

Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis

Authors Frieder Bauss and Ralph C Schimmer

Published 15 March 2006 Volume 2006:2(1) Pages 3—18

Frieder Bauss1 and Ralph C Schimmer2

1Roche Diagnostics GmbH, Pharma Research Penzberg, Penzberg, Germany, 2Pharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, Switzerland

Abstract: Osteoporosis is a major healthcare problem that continues growing as the population ages. Sufferers become increasingly susceptible to fractures, which compromise physical and emotional health and increase healthcare costs. Bisphosphonates are the most widely used medicines for the treatment and prevention of postmenopausal osteoporosis. However, therapeutic adherence is suboptimal, meaning that outcomes demonstrated in clinical trials are not realized in the real world. It is anticipated that reducing dosing frequency may facilitate medication intake and thereby improve adherence. Ibandronate is a potent nitrogen-containing bisphosphonate specifically developed for administration with long dose-free intervals. The comprehensive ibandronate preclinical development program has demonstrated dose-dependent improvements or preservation of bone quality and strength. The feasibility of intermittent dosing using the same total dose level as continuous dosing was also confirmed. In postmenopausal osteoporosis, once-monthly oral ibandronate has been shown to be therapeutically equivalent and even superior to daily oral ibandronate, which has demonstrated antifracture efficacy for vertebral and nonvertebral fractures, bone mineral density gains at the spine and hip, and reduction in bone resorption to premenopausal levels. Once-monthly oral ibandronate is also associated with excellent safety and tolerability, and promises to further improve therapeutic adherence to bisphosphonate treatment, thereby enhancing therapeutic outcomes.


Keywords: monthly, ibandronate, osteoporosis, bisphosphonate

Download Article [PDF] 

Readers of this article also read:

A common data model to assess cardiovascular hospitalization and mortality in atrial fibrillation patients using administrative claims and medical records

Panaccio MP, Cummins G, Wentworth C, Lanes S, Reynolds SL, Reynolds MW, Miao R, Koren A

Clinical Epidemiology 2015, 7:77-90

Published Date: 12 January 2015

A triple negative breast cancer: what it is not!

Katakkar SB

Breast Cancer: Targets and Therapy 2012, 4:21-23

Published Date: 24 February 2012

Erratum - Intracellular heavy metal nanoparticle storage

Iannitti T, Capone S, Gatti A, et al

International Journal of Nanomedicine 2011, 6:239-240

Published Date: 26 January 2011

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate

Omar S Din, Penella J Woll

Therapeutics and Clinical Risk Management 2008, 4:149-162

Published Date: 8 February 2008

A review of topotecan in combination chemotherapy for advanced cervical cancer

Minoo Robati, David Holtz, Charles J Dunton

Therapeutics and Clinical Risk Management 2008, 4:213-218

Published Date: 8 February 2008

Review of photodynamic therapy in actinic keratosis and basal cell carcinoma

Marica B Ericson, Ann-Marie Wennberg, Olle Larkö

Therapeutics and Clinical Risk Management 2008, 4:1-9

Published Date: 8 February 2008

Serotonin receptor modulators in the treatment of irritable bowel syndrome

Mohammad Fayyaz, Jeffrey M Lackner

Therapeutics and Clinical Risk Management 2008, 4:41-48

Published Date: 8 February 2008

The use of amisulpride in the treatment of acute psychosis

Philippe Nuss, Martina Hummer, Cédric Tessier

Therapeutics and Clinical Risk Management 2007, 3:3-11

Published Date: 15 March 2007